Thursday, 24 April 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 24 April 2025
News

Sanofi flashes blockbuster arsenal

Posted 24 April 2025 AM

Two highly anticipated drugs, each with sales expected to surpass the $1 billion mark in the coming years, are among six new products to make their first regulatory appearance in Australia – and they both belong to Sanofi.

This includes Sanofi’s BTK inhibitor tolebrutinib which has been granted the priority review pathway in multiple sclerosis plus the company’s efanesoctocog alfa, known as Altuviiio overseas, which has received an orphan drug designation for the treatment of haemophilia A.

To see the whole article, please login

Popular

Biologics to double COPD market
Who's spending the most on HCPs?
Top earning CEO crown goes to...
PBS could become a 'brutal jungle'
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home